RxDoctor Payments Data

Kacie Labik, PA

Medical · Phoenixville, PANPI 1427450196

Payments from drug & device makers

$2,223in general payments, 2019–2025

Across 94 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$341
  • AbbVie$259
  • Biohaven Pharmaceuticals, Inc.$203
  • GSK$171
  • Lilly USA, LLC$171
  • AstraZeneca$142
  • plus $936 from 23 others

What the payments were for

  • Food & beverage$2,223100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,223 in reported general payments places this provider in the 80th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$51,755
Medicare patients
193
Services billed
930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$25,042
JardianceEmpagliflozin24$23,497
MounjaroTirzepatide16$16,834
TrulicityDulaglutide17$16,100
XareltoRivaroxaban16$14,190
JanuviaSitagliptin Phosphate12$13,052
EliquisApixaban22$12,813
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,415
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$4,101
Albuterol Sulfate HfaAlbuterol Sulfate83$2,329
Pantoprazole Sodium105$1,920
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,476
Levothyroxine Sodium111$1,274
Atorvastatin Calcium150$1,259
Metoprolol Succinate78$1,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$171$32,93433 claims
Novo NordiskOzempic$341$25,04224 claims
Boehringer IngelheimJardiance$101$23,49724 claims
Johnson & JohnsonXarelto$19$14,19016 claims
MerckJanuvia$80$13,05212 claims
PfizerEliquis$49$12,81322 claims
GSKTrelegy Ellipta$171$12,41512 claims
AbbVieSynthroid$259$97617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Phoenixville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →